AC
NVCR icon

Aristides Capital’s NovoCure NVCR Stock Holding History

Aristides Capital’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,400
Closed -$178K – 343
2024
Q3 		$178K Hold
11,400
– – 0.06% 216
2024
Q2 		$195K Hold
11,400
– – 0.06% 232
2024
Q1 		$178K Buy
+11,400
New +$168K 0.07% 232

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Aristides Capital's NVCR Position: Q4 2024 in Review

Aristides Capital sold out of NovoCure (NVCR) in Q4 2024, closing a stake of 11,400 shares — an estimated $178K sold.

Aristides Capital first reported a position in NVCR in Q1 2024 and held it in 3 quarters. The position peaked at $195K in Q2 2024. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2024.

  • Aristides Capital reported no remaining NovoCure position as of Q4 2024 after selling out during the quarter.
  • Aristides Capital sold 11,400 NovoCure shares in Q4 2024, an estimated $178K.
  • Aristides Capital first reported a position in NovoCure in Q1 2024 and held it in 3 quarters.
  • Aristides Capital's NovoCure position peaked at $195K in Q2 2024.
  • 238 funds tracked by Wall St. Rank held NovoCure as of Q4 2024.

Based on Aristides Capital's 13F filing for Q4 2024, filed 13 Feb 2025.